Abstract:Background Glycogen synthase kinase-3 beta (GSK-3 beta), a serine/threonine protein kinase, may function as a tumor suppressor or an oncogene, depending on the tumor type. We sought to determine the biological function of GSK-3 beta in osteosarcoma, a rare pediatric cancer for which the identification of new therapeutic targets is urgent.Methods We used cell viability assays, colony formation assays, and apoptosis assays to analyze the effects of altered GSK-3 beta expression in U2OS, MG63, SAOS2, U2OS/MTX300, and ZOS osteosarcoma cell lines. Nude mice (n = 5-8 mice per group) were injected with U2OS/MTX300, and ZOS cells to assess the role of GSK-3 beta in osteosarcoma growth in vivo and to evaluate the effects of inhibitors and/or anticancer drugs on tumor growth. We used an antibody array, polymerase chain reaction, western blotting, and a luciferase reporter assay to establish the effect of GSK-3 beta inhibition on the nuclear factor-kappa B (NF-kappa B) pathway. Immunochemistry was performed on primary tumor specimens from osteosarcoma patients (n = 74) to determine the relationship of GSK-3 beta activity with overall survival.Results Osteosarcoma cells with low levels of inactive p-Ser9-GSK-3 beta formed colonies in vitro and tumors in vivo more readily than cells with higher levels and cells in which GSK-3 beta had been silenced formed fewer colonies and smaller tumors than parental cells. Silencing or pharmacological inhibition of GSK-3 beta resulted in apoptosis of osteosarcoma cells. Inhibition of GSK-3 beta resulted in inhibition of the NF-kappa B pathway and reduction of NF-kappa B-mediated transcription. Combination treatments with GSK-3 beta inhibitors, NF-kappa B inhibitors, and chemotherapy drugs increased the effectiveness of chemotherapy drugs in vitro and in vivo. Patients whose osteosarcoma specimens had hyperactive GSK-3 beta, and nuclear NF-kappa B had a shorter median overall survival time (49.2 months) compared with patients whose tumors had inactive GSK-3 beta and NF-kappa B (109.2 months).Conclusion GSK-3 beta activity may promote osteosarcoma tumor growth, and therapeutic targeting of the GSK-3 beta and/or NF-kappa B pathways may be an effective way to enhance the therapeutic activity of anticancer drugs against osteosarcoma.

Deduction of CDC42EP3 suppress development and progression of osteosarcoma

Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

DEPDC1/ EEF1A1 Complex Promotes the Progression of Human Osteosarcoma via Downregulation of FOXO3a

MicroRNA-455-3p Inhibits Osteosarcoma Progression Via HSF1 Downregulation

Figure S5 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Table S3 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Downregulation of Cdc6 Inhibits Tumorigenesis of Osteosarcoma in Vivo and in Vitro.

Circ_0003732 promotes osteosarcoma progression through regulating miR-377-3p/CPEB1 axis and Wnt/-catenin signaling pathway

(E)-SIS3 Suppressed Osteosarcoma Progression Via Promoting Cell Apoptosis, Arresting Cell Cycle, and Regulating the Tumor Immune Microenvironment

EID3 Promotes Cancer Stem Cell-Like Phenotypes in Osteosarcoma through the Activation of PI3K-AKT Signaling Pathway

PDCD10 Promotes Proliferation, Migration, and Invasion of Osteosarcoma by Inhibiting Apoptosis and Activating EMT Pathway

DEPDC1 as a crucial factor in the progression of human osteosarcoma

USP3 promotes osteosarcoma progression via deubiquitinating EPHA2 and activating the PI3K/AKT signaling pathway

Glycogen Synthase Kinase-3β, NF-κB Signaling, and Tumorigenesis of Human Osteosarcoma

Silencing of cytoskeleton-associated protein 2 represses cell proliferation and induces cell cycle arrest and cell apoptosis in osteosarcoma cells.

WITHDRAWN: PADI4 Regulates Osteosarcoma Proliferation Primarily Via Wnt/β-catenin and MEK/ERK Signaling Pathway

Diaphanous related formin 3 knockdown suppresses cell proliferation and metastasis of osteosarcoma cells

The Role of Mekk3 in Osteosarcoma Invasion and Metastasis

FGD1 Promotes Tumor Progression and Regulates Tumor Immune Response in Osteosarcoma Via Inhibiting PTEN Activity.

DownRegulated SOX4 Expression Suppresses Cell Proliferation, Migration, and Induces Apoptosis in Osteosarcoma In Vitro and In Vivo

Overexpression of Notch3 is associated with metastasis and poor prognosis in osteosarcoma patients.